Paper · 41678281

Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma.

Werr L and 46 others. J Clin Invest, 2026. Cited by 0 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma. Papers, record 41678281. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41678281

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma.; PubMed
Journal: J Clin Invest; PubMed
Year: 2026; PubMed
Publication types: Journal Article; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/41678281/; PubMed
DOI: https://doi.org/10.1172/jci189152; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13038208/; PubMed
The journal: https://conductscience.org/library/journal-index/7802877; PubMed
Citations, by iCite: 0; iCite
Revised in PubMed: 2026-08-13; PubMed

Authors47

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Werr L	Lisa
2	Boland J	Jana
3	Petersen J	Josephine
4	Iglesias F	Fiorella
5	Höppner S	Stefanie
6	Bartenhagen C	Christoph
7	Rosswog C	Carolina
8	Hellmann AM	Anna-Maria
9	Kahlert Y	Yvonne
10	Hemstedt N	Nadine

1 to 10 of 47Source PubMed

See all 47 authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Receptor, Fibroblast Growth Factor, Type 1	Major topic
Neuroblastoma	Major topic
Mutation	Major topic
Neoplasm Proteins	Major topic
Animals
Humans
Mice
Mice, Transgenic
Cell Line, Tumor
Female

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by
P30 CA008748	NCI NIH HHS	United States	P30CA008748	PubMed

Source NIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References68

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	19,224,897	The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations.	Sci Signal	2009	https://conductscience.org/library/papers/19224897	PubMed
2	35,247,925	CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization.	Mol Cancer Ther	2022	https://conductscience.org/library/papers/35247925	PubMed
3	9,009,090	Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis.	Leukemia	1997	https://conductscience.org/library/papers/9009090	PubMed
4	22,388,515	Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer.	Clin Cancer Res	2012	https://conductscience.org/library/papers/22388515	PubMed
5	22,789,543	The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.	Cancer Cell	2012	https://conductscience.org/library/papers/22789543	PubMed
6	26,121,086	Mutational dynamics between primary and relapse neuroblastomas.	Nat Genet	2015	https://conductscience.org/library/papers/26121086	PubMed
7	18,948,947	Somatic mutations affect key pathways in lung adenocarcinoma.	Nature	2008	https://conductscience.org/library/papers/18948947	PubMed
8	32,622,884	Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.	Ann Oncol	2020	https://conductscience.org/library/papers/32622884	PubMed
9	28,561,228	2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors.	Klin Padiatr	2017	https://conductscience.org/library/papers/28561228	PubMed
10	16,199,517	Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.	Proc Natl Acad Sci U S A	2005	https://conductscience.org/library/papers/16199517	PubMed

1 to 10 of 68

See all 68 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

None in this release.

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
FGFR1	2,260	PubTator's text mining	https://conductscience.org/library/genes/2260	NCBI Gene
IL3	3,562	PubTator's text mining	https://conductscience.org/library/genes/3562	NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41678281

GET https://conductscience.org/api/papers/v1/41678281/authors?page=2

API reference For AI assistants